These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26368060)

  • 1. Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe.
    Matusewicz W; Godman B; Pedersen HB; Fürst J; Gulbinovič J; Mack A; Selke G; Timoney A; Warmińska E; Malmström RE
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):755-8. PubMed ID: 26368060
    [No Abstract]   [Full Text] [Related]  

  • 2. Improving the managed entry of new medicines: sharing experiences across Europe.
    Godman B; Paterson K; Malmström RE; Selke G; Fagot JP; Mrak J
    Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):439-41. PubMed ID: 22971029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European Medicines Agency is attacked over proposal to allow technology assessment bodies to sell advice to drug industry.
    Wise J
    BMJ; 2014 Jul; 349():g4674. PubMed ID: 25033980
    [No Abstract]   [Full Text] [Related]  

  • 4. The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications.
    Ferrario A; Arāja D; Bochenek T; Čatić T; Dankó D; Dimitrova M; Fürst J; Greičiūtė-Kuprijanov I; Hoxha I; Jakupi A; Laidmäe E; Löblová O; Mardare I; Markovic-Pekovic V; Meshkov D; Novakovic T; Petrova G; Pomorski M; Tomek D; Voncina L; Haycox A; Kanavos P; Vella Bonanno P; Godman B
    Pharmacoeconomics; 2017 Dec; 35(12):1271-1285. PubMed ID: 28836222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity.
    Linley WG; Hughes DA
    Pharmacoeconomics; 2013 Apr; 31(4):345-55. PubMed ID: 23516033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric microdose and microtracer studies using 14C in Europe.
    Turner MA; Mooij MG; Vaes WH; Windhorst AD; Hendrikse NH; Knibbe CA; Kõrgvee LT; Maruszak W; Grynkiewicz G; Garner RC; Tibboel D; Park BK; de Wildt SN
    Clin Pharmacol Ther; 2015 Sep; 98(3):234-7. PubMed ID: 26095095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA new drug approvals in Q3 2019.
    Urquhart L
    Nat Rev Drug Discov; 2019 Oct; 18(11):816. PubMed ID: 31673140
    [No Abstract]   [Full Text] [Related]  

  • 8. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. We want our money back!
    Prescrire Int; 2011 Apr; 20(115):88. PubMed ID: 21648205
    [No Abstract]   [Full Text] [Related]  

  • 10. New drugs for old: disinvestment and NICE.
    Hughes DA; Ferner RE
    BMJ; 2010 Feb; 340():c572. PubMed ID: 20185495
    [No Abstract]   [Full Text] [Related]  

  • 11. The Innovative Medicines Initiative: a pre-competitive initiative to enhance the biomedical science base of Europe to expedite the development of new medicines for patients.
    Hunter AJ
    Drug Discov Today; 2008 May; 13(9-10):371-3. PubMed ID: 18468553
    [No Abstract]   [Full Text] [Related]  

  • 12. The Supercar Stays in the Garage: Factors Preventing Indirect Comparisons of Novel Medicines Targeting the Same Condition.
    Ollendorf DA; Kim E; Bridger N; Naci H
    J Manag Care Spec Pharm; 2020 Mar; 26(3):333-334. PubMed ID: 32105173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orphan drug development across Europe: bottlenecks and opportunities.
    Heemstra HE; de Vrueh RL; van Weely S; Büller HA; Leufkens HG
    Drug Discov Today; 2008 Aug; 13(15-16):670-6. PubMed ID: 18583178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicines regulation and health technology assessment.
    Breckenridge A; Woods K; Walley T
    Clin Pharmacol Ther; 2010 Feb; 87(2):152-4. PubMed ID: 20107448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New drugs and indications in 2012. Sluggish progress, timid measures to protect patients.
    Prescrire Int; 2013 Apr; 22(137):105-7. PubMed ID: 23662323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health technology assessment in the United Kingdom.
    Akehurst R
    Value Health; 2010 Jun; 13 Suppl 1():S4-5. PubMed ID: 20618794
    [No Abstract]   [Full Text] [Related]  

  • 17. [EURO-Medicines: a European program for bringing into agreement public health policies on drugs].
    Calamo-Specchia F; Bucci R; Folino-Gallo P
    Ann Ig; 1998; 10(5-6):405-12. PubMed ID: 10052204
    [No Abstract]   [Full Text] [Related]  

  • 18. Why licensing authorities need to consider the net value of new drugs in assigning review priorities: addressing the tension between licensing and reimbursement.
    McCabe C; Claxton K; O'Hagan A
    Int J Technol Assess Health Care; 2008; 24(2):140-5. PubMed ID: 18400115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit-risk assessment: to quantify or not to quantify, that is the question.
    Yuan Z; Levitan B; Berlin JA
    Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):653-6. PubMed ID: 21538675
    [No Abstract]   [Full Text] [Related]  

  • 20. Health Technology Assessment in the Context of Adaptive Pathways for Medicines in Europe: Challenges and Opportunities.
    Bouvy JC; Jonsson P; Longson C; Crabb N; Garner S
    Clin Pharmacol Ther; 2016 Dec; 100(6):594-597. PubMed ID: 27530105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.